文献速递胸部肿瘤

拉泽替尼对比吉非替尼一线治疗EGFR突变晚期非小细胞肺癌:LASER301研究结果

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301.
PubMed 文献 · J Clin Oncol · 2023-06-28

LASER301是一项全球III期研究,在初治EGFR突变(19外显子缺失/L858R)局部晚期或转移性非小细胞肺癌患者中比较拉泽替尼240 mg每日一次与吉非替尼250 mg每日一次。主要终点研究者评估的无进展生存期拉泽替尼组显著长于吉非替尼组(20.6个月 vs 9.7个月;HR 0.45;95%CI 0.34-0.58;P<.001)。两组客观缓解率均为76%,总生存数据尚未成熟。

要点

  • 拉泽替尼一线治疗EGFR突变晚期NSCLC的中位无进展生存期为20.6个月,吉非替尼为9.7个月(HR 0.45;95%CI 0.34-0.58;P<.001)。
  • 两组客观缓解率均为76%(OR 0.99;95%CI 0.62-1.59),拉泽替尼中位缓解持续时间19.4个月,吉非替尼8.3个月。
  • 总生存数据尚未成熟(成熟度29%),18个月生存率拉泽替尼组80%、吉非替尼组72%(HR 0.74;95%CI 0.51-1.08;P=.116)。

核心结论

  • 拉泽替尼对比吉非替尼一线治疗EGFR突变晚期非小细胞肺癌显著改善疗效,安全性可控。

研究设计与样本

  • 全球、III期研究(LASER301),在13个国家96个中心开展。
  • 393例初治EGFR突变(19外显子缺失/L858R)局部晚期或转移性非小细胞肺癌患者随机1:1接受拉泽替尼240 mg每日一次口服或吉非替尼250 mg每日一次口服,按突变状态和种族分层。
  • 允许神经学稳定的中枢神经系统转移患者入组,患者年龄18岁及以上且无既往系统性抗肿瘤治疗。
  • 主要终点为研究者按RECIST v1.1评估的无进展生存期。

主要发现

  • 拉泽替尼组中位无进展生存期20.6个月,吉非替尼组9.7个月(HR 0.45;95%CI 0.34-0.58;P<.001)。
  • 拉泽替尼对比吉非替尼的无进展生存期获益在所有预设亚组中一致。
  • 两组客观缓解率均为76%(OR 0.99;95%CI 0.62-1.59)。
  • 拉泽替尼组中位缓解持续时间19.4个月(95%CI 16.6-24.9),吉非替尼组8.3个月(95%CI 6.9-10.9)。
  • 总生存数据在 interim 分析时尚未成熟(成熟度29%),18个月生存率拉泽替尼组80%、吉非替尼组72%(HR 0.74;95%CI 0.51-1.08;P=.116)。

局限性

  • 总生存数据在 interim 分析时尚未成熟(成熟度29%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Lazertinib is a potent, CNS-penetrant, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This global, phase III study (LASER301) compared lazertinib versus gefitinib in treatment-naïve patients with EGFR-mutated (exon 19 deletion [ex19del]/L858R) locally advanced or metastatic non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients were 18 years and older with no previous systemic anticancer therapy. Neurologically stable patients with CNS metastases were allowed. Patients were randomly assigned 1:1 to lazertinib 240 mg once daily orally or gefitinib 250 mg once daily orally, stratified by mutation status and race. The primary end point was investigator-assessed progression-free survival (PFS) by RECIST v1.1. RESULTS: Overall, 393 patients received double-blind study treatment across 96 sites in 13 countries. Median PFS was significantly longer with lazertinib than with gefitinib (20.6 v 9.7 months; hazard ratio [HR], 0.45; 95% CI, 0.34 to 0.58; P < .001). The PFS benefit of lazertinib over gefitinib was consistent across all predefined subgroups. The objective response rate was 76% in both groups (odds ratio, 0.99; 95% CI, 0.62 to 1.59). Median duration of response was 19.4 months (95% CI, 16.6 to 24.9) with lazertinib versus 8.3 months (95% CI, 6.9 to 10.9) with gefitinib. Overall survival data were immature at the interim analysis (29% maturity). The 18-month survival rate was 80% with lazertinib and 72% with gefitinib (HR, 0.74; 95% CI, 0.51 to 1.08; P = .116). Observed safety of both treatments was consistent with their previously reported safety profiles. CONCLUSION: Lazertinib demonstrated significant efficacy improvement compared with gefitinib in the first-line treatment of EGFR-mutated advanced NSCLC, with a manageable safety profile.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Cho BC, Ahn MJ, Kang JH, et al. Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301. J Clin Oncol. 2023. PMID: 37379502. doi:10.1200/JCO.23.00515

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。